Method for preparing chiral 4-aryl-β-amino acid derivative
AssigneeZhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
InventorsLi Sheng, Xufeng Wu, Dadong Shen, Gang Fan, Pengcheng Liu, Dengfeng Dong
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for preparing a chiral 4-aryl-β-amino acid derivative. The preparation method comprises hydrogenating an enamine compound having a structure as shown in Formula III in an organic solvent in the presence of a catalyst containing a transition metal and BIBOPs. The preparation method of the present invention uses a small amount of a selected asymmetric catalyst, and has a simple operation, mild reaction conditions, a high yield, a high stereoselectivity, and better industrial application and economic values.
Claims8
A method for preparing a chiral 4-aryl-β-amino acid derivative having a structure as shown in Formula I,
- wherein R-configuration or S-configuration is marked with * in the stereocenter;
- the method comprising hydrogenating an enamine compound having a structure as shown in Formula III in an organic solvent in the presence of a catalyst containing a transition metal and BIBOPs;
- wherein Ar is a phenyl, substituted with 1-5 substituents or a mixture of 1-5 substituents independently selected from halogen, trifluoromethyl, and alkoxy;
- PG is hydrogen, an aldehyde group, acetyl, benzyl, Boc, Cbz, PMB, Fmoc, COOR1, or CONR2;
- Z is OR1, SR1 or NR3R4;
- wherein
- R1 is H or C1-6 alkyl;
- R2 is H, C1-6 alkyl, or a three-membered to six-membered heterocycle containing nitrogen, oxygen, and sulfur;
- R3 and R4 are each independently H, C1-6 alkyl, C4-10 cycloalkyl, aryl, or R3 and R4 bonded to the nitrogen atom form a C4-7 membered heterocycle optionally having an additional heteroatom independently selected from O, S, and N—C1-5 alkyl;
- wherein the transition metal comprises [M(COD)2]X,
- wherein X is selected from an uncoordinated anion of tetrafluoroborate, hexafluoroantimonate, and trifluoromethanesulfonate;
- M is rhodium, iridium, or ruthenium;
- wherein a ligand BIBOPs has a structure as shown in Formula IV:
- wherein R′ is hydrogen, alkyl, halogen, hydroxyl, alkoxy, or aryl.
Dependencies are inferred from the claim text.